Cycle Pharmaceuticals Ltd. and its subsidiary AT2B, Inc. extended the deadline for its tender offer to purchase all outstanding shares of Applied Therapeutics, Inc. The offer, originally set to expire at 11:59 p.m. Eastern on January 27, 2026, now runs until 11:59 p.m. Eastern on January 28, 2026. Shareholders may still tender shares at the offer price of $0.088 per share plus one non‑tradeable contingent value right (CVR) per share.
Applied Therapeutics has been in a precarious financial position, with cash and cash equivalents falling from $79.4 million at the end of 2024 to $11.9 million by September 30, 2025. The company’s research and development spend has also declined, reflecting cost‑cutting measures. A recent FDA Complete Response Letter for its lead candidate govorestat, aimed at classic galactosemia, added regulatory uncertainty and further pressured the company’s valuation. These factors explain the modest cash offer and the inclusion of a CVR to provide upside potential tied to future milestones.
The acquisition aligns strategically with Cycle’s focus on rare‑disease therapeutics. Both companies are developing treatments for rare metabolic disorders, and Cycle’s broader pipeline and resources could accelerate the development of govorestat and other Applied candidates. Management has indicated that the deal will provide Applied with the capital and infrastructure needed to continue its research, while Cycle gains a promising asset that complements its existing portfolio.
The CVR attached to each share offers potential future payments if govorestat or other Applied products achieve regulatory approval or reach specified sales milestones. The right is non‑tradeable and will be exercised only if the company meets the agreed milestones, providing shareholders with a contingent upside that reflects the uncertain but potentially high value of the pipeline.
The extension gives Applied shareholders additional time to evaluate the offer and decide whether to tender their shares. If a majority of shares are tendered by the new deadline, the acquisition will close and Applied will become a wholly owned subsidiary of Cycle. If the majority threshold is not met, the offer will lapse and Applied will remain independent, potentially seeking alternative financing or strategic options. The outcome will have a direct impact on the future of Applied’s pipeline and the strategic direction of Cycle’s rare‑disease portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.